These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2223581)

  • 1. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
    Moseley RP; Davies AG; Richardson RB; Zalutsky M; Carrell S; Fabre J; Slack N; Bullimore J; Pizer B; Papanastassiou V
    Br J Cancer; 1990 Oct; 62(4):637-42. PubMed ID: 2223581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates.
    Moseley RP; Papanastassiou V; Zalutsky MR; Ashpole RD; Evans S; Bigner DD; Kemshead JT
    Int J Cancer; 1992 Aug; 52(1):38-43. PubMed ID: 1500225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates.
    Kemshead JT; Hopkins KI; Chandler CL
    Recent Results Cancer Res; 1996; 141():145-58. PubMed ID: 8722425
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors.
    Lashford LS; Davies AG; Richardson RB; Bourne SP; Bullimore JA; Eckert H; Kemshead JT; Coakham HB
    Cancer; 1988 Mar; 61(5):857-68. PubMed ID: 3338052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients.
    Coakham HB; Kemshead JT
    J Neurooncol; 1998; 38(2-3):225-32. PubMed ID: 9696376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.
    Papanastassiou V; Pizer BL; Coakham HB; Bullimore J; Zananiri T; Kemshead JT
    Br J Cancer; 1993 Jan; 67(1):144-51. PubMed ID: 8427774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
    Press OW; Eary JF; Badger CC; Martin PJ; Appelbaum FR; Levy R; Miller R; Brown S; Nelp WB; Krohn KA
    J Clin Oncol; 1989 Aug; 7(8):1027-38. PubMed ID: 2666588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8.
    Kramer K; Humm JL; Souweidane MM; Zanzonico PB; Dunkel IJ; Gerald WL; Khakoo Y; Yeh SD; Yeung HW; Finn RD; Wolden SL; Larson SM; Cheung NK
    J Clin Oncol; 2007 Dec; 25(34):5465-70. PubMed ID: 18048828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children.
    Pizer B; Papanastassiou V; Hancock J; Cassano W; Coakham H; Kemshead J
    Br J Haematol; 1991 Apr; 77(4):466-72. PubMed ID: 2025571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.
    Stewart JS; Hird V; Snook D; Sullivan M; Hooker G; Courtenay-Luck N; Sivolapenko G; Griffiths M; Myers MJ; Lambert HE
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):405-13. PubMed ID: 2921145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis.
    Richardson RB; Kemshead JT; Davies AG; Staddon GE; Jackson PC; Coakham HB; Lashford LS
    Eur J Nucl Med; 1990; 17(1-2):42-8. PubMed ID: 2083542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody.
    Benjamin JC; Moss T; Moseley RP; Maxwell R; Coakham HB
    Neurosurgery; 1989 Aug; 25(2):253-8. PubMed ID: 2770989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.
    Kemshead JT; Hopkins K; Pizer B; Papanastassiou V; Coakham H; Bullimore J; Chandler C
    Br J Cancer; 1998 Jun; 77(12):2324-30. PubMed ID: 9649153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinomatous meningitis: antibody-guided therapy with I-131 HMFG1.
    Moseley RP; Benjamin JC; Ashpole RD; Sullivan NM; Bullimore JA; Coakham HB; Kemshead JT
    J Neurol Neurosurg Psychiatry; 1991 Mar; 54(3):260-5. PubMed ID: 2030355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.